Eiger BioPharmaceuticals, Inc.: M&A transaction — Eiger sells lonafarnib ($5.2M) and peginterferon lambda ($1M) assets in Ch11; closings Sept 3

Eiger BioPharmaceuticals, Inc.

Bankruptcy Court approved both asset sales on August 20, 2024; closings occurred September 3, 2024.
Lonafarnib antiviral assets sold to Eiger InnoTherapeutics for $5.2M plus cure costs and assumed liabilities.
Peginterferon lambda-1a assets sold to same buyer for $1.0M plus cure costs and assumed liabilities.
Company warns securityholders may face significant or total loss on investment given Chapter 11 outcome.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Eiger BioPharmaceuticals, Inc. completed a disposition involving Eiger InnoTherapeutics, Inc. for $5.2 million (closed 2024-09-03).

Action: disposition
Counterparty: Eiger InnoTherapeutics, Inc.
Consideration: $5.2 million
Closing: 2024-09-03

Exact text from the filing

Lonafarnib Antiviral Asset Sale On August 1, 2024, the Company and Eiger InnoTherapeutics, Inc. (the “ Purchaser ”) entered into that certain Lonafarnib Asset Purchase Agreement, pursuant to which the Purchaser agreed to acquire all of the Company’s rights, title and interests in, to and under the assets and interests used in the business related to the development, manufacture and commercialization of certain lonafarnib antiviral products for $5.2 million, plus a portion of the cure costs with respect to assigned contracts and the assumption of specified liabilities.

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Eiger BioPharmaceuticals, Inc. completed a disposition involving Eiger InnoTherapeutics, Inc. for $1.0 million (closed 2024-09-03).

Action: disposition
Counterparty: Eiger InnoTherapeutics, Inc.
Consideration: $1.0 million
Closing: 2024-09-03

Exact text from the filing

Lonafarnib Antiviral Asset Sale On August 1, 2024, the Company and Eiger InnoTherapeutics, Inc. (the “ Purchaser ”) entered into that certain Lonafarnib Asset Purchase Agreement, pursuant to which the Purchaser agreed to acquire all of the Company’s rights, title and interests in, to and under the assets and interests used in the business related to the development, manufacture and commercialization of certain lonafarnib antiviral products for $5.2 million, plus a portion of the cure costs with respect to assigned contracts and the assumption of specified liabilities.

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001193125-24-212606

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.